在接受新辅助化疗或放射治疗的患有直肠癌的糖尿病患者中,甲福明对瘤回归度的影响
Nai-Yu Lin1, Kun-Yu Tsai2, Yen-Lin Huang3
1Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital at Linkou, No.5, Fuxing Street, Guishan District, Taoyuan, 333, Taiwan.
Scientific reports
|July 16, 2025
概括
在接受新辅助化学放射治疗的局部晚期直肠癌患者中,使用甲胺可能会改善瘤反应,特别是增强瘤回归度 (TRG). 然而,整体存活率和无病存活率没有显著影响.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 局部晚期直肠癌 (LARC) 需要有效的新辅助治疗.
- 新辅助化学放射治疗 (nCRT) 是LARC的标准治疗方法.
- 目前正在研究一种常见的糖尿病药物 - - 甲胺在癌症治疗中的作用.
研究的目的:
- 评估甲胺对LARC.患者nCRT疗法疗效的影响.
- 评估甲福明的使用是否影响瘤回归和生存结果.
主要方法:
- 对直肠腺癌患者 (2005-2019) 的回顾性,单一机构研究.
- 甲双使用者 (n=56) 和非甲双使用者 (n=33) 的结果比较.
- 主要结局:瘤回归度 (TRG);次要结局:复发,T下阶段,无病生存期 (DFS),整体生存期 (OS).
主要成果:
- 甲胺使用者显示TRG显著改善 (p=0.006).
- 两组之间没有OS或DFS的显著差异.
- 观察到甲福明剂量与TRG之间的潜在关联.
结论:
- 甲福明可能会增强直肠癌中对nCRT的反应,特别是TRG.
- 需要进一步的研究来证实这些发现,并确定最佳的甲福林治疗方案.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
306
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
306
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
327
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
327


